Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 11;8(8):CD010069.
doi: 10.1002/14651858.CD010069.pub3.

Interventions for tophi in gout

Melonie K Sriranganathan  1 , Ophir Vinik  2 , Jordi Pardo Pardo  3 , Claire Bombardier  4 , Christopher J Edwards  5
Affiliations

Interventions for tophi in gout

Melonie K Sriranganathan et al. Cochrane Database Syst Rev. .

Abstract

Background: Tophi develop in untreated or uncontrolled gout. This is an update of a Cochrane Review first published in 2014. OBJECTIVES: To assess the benefits and harms of non-surgical and surgical treatments for the management of tophi in gout.

Search methods: We updated the search of Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase databases to 28 August 2020.

Selection criteria: We included all published randomised controlled trials (RCTs) or controlled clinical trials examining interventions for tophi in gout in adults.

Data collection and analysis: We used standard methodological procedures expected by Cochrane.

Main results: We included one trial in our original review. We added four more trials (1796 participants) in this update. One had three arms; pegloticase infusion every two weeks (biweekly), monthly pegloticase infusion (pegloticase infusion alternating with placebo infusion every two weeks) and placebo. Two studies looked at lesinurad 200 mg or 400 mg in combination with allopurinol. One trial studied lesinurad 200 mg or 400 mg in combination with febuxostat. One trial compared febuxostat 80 mg and 120 mg to allopurinol. Two trials were at unclear risk of performance and detection bias due to lack of information on blinding of participants and personnel. All other trials were at low risk of bias. Moderate-certainty evidence (downgraded for imprecision; one study; 79 participants) showed that biweekly pegloticase resolved tophi in 21/52 participants compared with 2/27 on placebo (risk ratio (RR) 5.45, 95% confidence interval (CI) 1.38 to 21.54; number needed to treat for a benefit (NNTB) 3, 95% CI 2 to 6). Similar proportions of participants receiving biweekly pegloticase (80/85) had an adverse event compared to placebo (41/43) (RR 0.99, 95% CI 0.91 to 1.07). However, more participants on biweekly pegloticase (15/85) withdrew due to an adverse event compared to placebo (1/43) (RR 7.59, 95% CI 1.04 to 55.55; number needed to treat for a harm (NNTH) 7, 95% CI 4 to 16). More participants on monthly pegloticase (11/52) showed complete resolution of tophi compared with placebo (2/27) (RR 2.86, 95% CI 0.68 to 11.97; NNTB 8, 95% CI 4 to 91). Similar numbers of participants on monthly pegloticase (84/84) had an adverse event compared to placebo (41/43) (RR 1.05, 95% CI 0.98 to 1.14). More participants on monthly pegloticase (16/84) withdrew due to adverse events compared to placebo (1/43) (RR 8.19, 95% CI 1.12 to 59.71; NNTH 6, 95% CI 4 to 14). Infusion reaction was the most common reason for withdrawal. Moderate-certainty evidence (2 studies; 103 participants; downgraded for imprecision) showed no clinically significant difference for complete resolution of target tophus in the lesinurad 200 mg plus allopurinol arm (11/53) compared to the placebo plus allopurinol arm (16/50) (RR 0.40, 95% CI 0.04 to 4.57), or in the lesinurad 400 mg plus allopurinol arm (12/48) compared to the placebo plus allopurinol arm (16/50) (RR 0.79, 95% CI 0.42 to 1.49). An extension study examined lesinurad 200 mg or 400 mg in combination with febuxostat, or placebo (low-certainty evidence, downgraded for indirectness and imprecision). Participants on lesinurad in the original study continued (CONT) on the same dose. Lesinurad 400 mg plus febuxostat may be beneficial for tophi resolution; 43/65 in the lesinurad 400 mg CONT arm compared to 38/64 in the lesinurad 200 mg CONT arm had tophi resolution (RR 1.11, 95% CI 0.85 to 1.46). Lesinurad 400 mg plus febuxostat may result in no difference in adverse events; 57/65 in the lesinurad 400 mg CONT arm had an adverse event compared to 50/64 in lesinurad 200 mg CONT arm (RR 1.12, 95% CI 0.96 to 1.32). Lesinurad 400 mg plus febuxostat may result in no difference in withdrawals due to adverse events; 10/65 participants in the lesinurad 400 mg CONT arm withdrew due to an adverse event compared to 10/64 participants in the lesinurad 200 mg CONT arm (RR 0.98, 95% CI 0.44 to 2.20). Lesinurad 400 mg plus febuxostat may result in no difference in mean serum uric acid (sUA), which was 3 mg/dl in the lesinurad 400 mg CONT group compared to 3.9 mg/dl in the lesinurad 200 mg CONT group (mean difference -0.90, 95% CI -1.51 to -0.29). Participants who were not on lesinurad in the original study were randomised (CROSS) to lesinurad 200 mg or 400 mg, both in combination with febuxostat. Low-certainty evidence downgraded for indirectness and imprecision showed that lesinurad 400 mg (CROSS) may result in tophi resolution (17/34) compared to lesinurad 200 mg (CROSS) (14/33) (RR 1.18, 95% CI 0.70 to 1.98). Lesinurad 400 mg in combination with febuxostat may result in no difference in adverse events (33/34 in the lesinurad 400 mg CROSS arm compared to 27/33 in the lesinurad 200 mg (CROSS); RR 1.19, 95% CI 1.00 to 1.41). Lesinurad 400 mg plus febuxostat may result in no difference in withdrawals due to adverse events, 5/34 in the lesinurad 400 mg CROSS arm withdrew compared to 2/33 in the lesinurad 200 mg CROSS arm (RR 2.43, 95% CI 0.51 to 11.64). Lesinurad 400 mg plus febuxostat results in no difference in sUA (4.2 mg/dl in lesinurad 400 mg CROSS) compared to lesinurad 200 mg (3.8 mg/dl in lesinurad 200 mg CROSS), mean difference 0.40 mg/dl, 95% CI -0.75 to 1.55.

Authors' conclusions: Moderate-certainty evidence showed that pegloticase is probably beneficial for resolution of tophi in gout. Although there was little difference in adverse events when compared to placebo, participants on pegloticase had more withdrawals due to adverse events. Lesinurad 400 mg plus febuxostat may be beneficial for tophi resolution compared with lesinurad 200 mg plus febuxostat; there was no difference in adverse events between these groups. We were unable to determine whether lesinurad plus febuxostat is more effective than placebo. Lesinurad (400 mg or 200 mg) plus allopurinol is probably not beneficial for tophi resolution, and there was no difference in adverse events between these groups. RCTs on interventions for managing tophi in gout are needed, and the lack of trial data is surprising given that allopurinol is a well-established treatment for gout.

PubMed Disclaimer

Conflict of interest statement

MS none known

OV none known

JPP: none known

CB: none known

CE: none known

Figures

1
1
PRISMA Flow diagram for updated search 2020
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 1: Proportion with tophi resolution
1.2
1.2. Analysis
Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 2: Withdrawal due to adverse events
1.3
1.3. Analysis
Comparison 1: Pegloticase every two weeks (biweekly) versus placebo, Outcome 3: Total adverse events
2.1
2.1. Analysis
Comparison 2: Pegloticase monthly versus placebo, Outcome 1: Proportion with tophi resolution
2.2
2.2. Analysis
Comparison 2: Pegloticase monthly versus placebo, Outcome 2: Withdrawal due to adverse events
2.3
2.3. Analysis
Comparison 2: Pegloticase monthly versus placebo, Outcome 3: Total adverse events
3.1
3.1. Analysis
Comparison 3: Pegloticase every two weeks (biweekly) versus pegloticase monthly, Outcome 1: Proportion with tophi resolution
4.1
4.1. Analysis
Comparison 4: Lesinurad 200 mg plus allopurinol versus placebo plus allopurinol , Outcome 1: Complete resolution of a target tophus
5.1
5.1. Analysis
Comparison 5: Lesinurad 400 mg plus allopurinol versus placebo plus allopurinol, Outcome 1: Complete resolution of a target tophus
6.1
6.1. Analysis
Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 1: Complete resolution of a target tophus
6.2
6.2. Analysis
Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 2: Total adverse events
6.3
6.3. Analysis
Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 3: Withdrawal due to adverse event
6.4
6.4. Analysis
Comparison 6: Lesinurad 400 mg plus febuxostat CONTINUED versus lesinurad 200 mg plus febuxostat CONTINUED, Outcome 4: Mean serum uric acid (sUA) at end of 12 months
7.1
7.1. Analysis
Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 1: Complete resolution of a target tophus
7.2
7.2. Analysis
Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 2: Total adverse events
7.3
7.3. Analysis
Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 3: Withdrawal due to adverse event
7.4
7.4. Analysis
Comparison 7: Lesinurad 400 mg plus febuxostat CROSS versus lesinurad 200 mg plus febuxostat CROSS, Outcome 4: Mean serum uric acid (sUA) at end of 12 months
See this image and copyright information in PMC

Update of

Comment in

References

References to studies included in this review

Bardin 2017 {published data only}
    1. Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases 2017;76(5):811-20. [DOI: 10.1136/annrheumdis-2016-209213] - DOI - PMC - PubMed
Becker 2005 {published data only}
    1. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine December 8, 2005;353(23):2450-61. - PubMed
Dalbeth 2019 {published data only}
    1. Dalbeth, N, Jones, G, Terkeltaub, R, Khanna, D, Kopicko, J, Bhakta, N et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis & Rheumatology 2017;69:1903-13. - PMC - PubMed
    1. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research & Therapy 2019;21(1):8. [DOI: ] - PMC - PubMed
Saag 2017 {published data only}
    1. Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis & Rheumatology 2017;69(1):203-12. [DOI: 10.1002/art.39840] - DOI - PubMed
Sundy 2011 {published data only}
    1. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials. Journal of the American Medical Association 2011;306:711-20. [ClinicalTrials.gov Identifier NCT00325195] - PubMed

References to studies excluded from this review

Doherty 2018 {published data only}
    1. Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 2018;392(10156):1403-12. - PMC - PubMed
Fleischmann 2018 {published data only}
    1. Fleischmann R, Winkle P, Miner JN, Yan X, Hicks L, Valdez S, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. Rheumatic & Musculoskeletal Diseases Open 2018;4(1):e000584. - PMC - PubMed
Haber 2018 {published data only}
    1. Haber SL, Fente G, Fenton SN, Walker EP, Weaver BM, Cano AJ, et al. Lesinurad: a novel agent for management of chronic gout. Annals of Pharmacotherapy 2018;52(7):690-6. - PubMed
Hao 2019 {published data only}
    1. Hao G, Duan W, Sun J, Liu J, Peng B. Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-α and COX-2. Experimental and Therapeutic Medicine 2019;17(1):812-6. - PMC - PubMed
Hosoya 2018 {published data only}
    1. Hosoya T, Ishikawa T, Ogawa Y, Sakamoto R, Ohashi T. Multicenter, open-label study of long-term topiroxostat (FYX-051) administration in Japanese hyperuricemic patients with or without gout. Clinical Drug Investigation 2018;38(45):1135-43. - PMC - PubMed
Kankam 2018 {published data only}
    1. Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, et al. Pharmacokinetics, pharmacodynamics, and tolerability of concomitant multiple dose administration of verinurad (RDEA3170) and allopurinol in adult male subjects with gout. Journal of Clinical Pharmacology 2018;58(9):1214-22. - PMC - PubMed
Timilsina 2018 {published data only}
    1. Timilsina S, Brittan K, O'Dell JR, Brophy M, Davis-Karim A, Henrie AM, et al. Design and rationale for the Veterans Affairs "Cooperative study program 594 comparative effectiveness in gout: allopurinol vs. febuxostat" trial. Contemporary Clinical Trials 2018;68:102-8. - PubMed
White 2018 {published data only}
    1. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al, CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. New England Journal of Medicine 2018;378(13):1200-10. - PubMed

References to ongoing studies

CLEAR I and II Extension {published data only}
    1. A long-term extension study of lesinurad in combination with allopurinol for subjects completing an efficacy and safety study of lesinurad and allopurinol. Ongoing study. February 2013. Contact author for more information.
DISSOLVE I {published data only}
    1. A study of SEL-212 in patients with gout refractory to conventional therapy (DISSOLVE I). Ongoing study. 18 August 2020. Contact author for more information.
DISSOLVE II {published data only}
    1. A study of SEL-212 in patients with gout refractory to conventional therapy II (DISSOLVE II). Ongoing study. October 2020. Contact author for more information.
MIRROR RCT {published data only}
    1. A randomized, double-Blind, placebo-controlled, multicenter, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial (RCT)). Ongoing study. 13 June 2019. Contact author for more information.

Additional references

Anderson 2010
    1. Anderson A, Singh JA. Pegloticase for chronic gout. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No: CD008335. [DOI: 10.1002/14651858.CD008335.pub2] - DOI - PMC - PubMed
Cates 2008
    1. Cates 2008. Visual Rx [Computer program]. Version 3; 2008. Available at: www.nntonline.net.
Covidence [Computer program]
    1. Covidence. Version accessed September 2020. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.
Deeks 2020
    1. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
FitzGerald 2020
    1. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research 2020;72(6):744-60. - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed January 2021. Hamilton (ON): McMaster University (developed by EvidencePrime). Available at gradepro.org.
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.1/.
Khanna 2012
    1. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al, American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research 2012;64(10):1431-46. - PMC - PubMed
Page 2020
    1. Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
Schlesinger 2011
    1. Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 2011;71(11):1413-39. - PubMed
Schünemann 2020a
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
Schünemann 2020b
    1. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook..
Terkeltaub 2003
    1. Terkeltaub RA. Gout. New England Journal of Medicine 2003;349:1647-55. - PubMed

References to other published versions of this review

Sriranganathan 2014
    1. Sriranganathan MK, Vinik O, Bombardier C, Edwards CJ. Interventions for tophi in gout. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No: CD010069. [DOI: 10.1002/14651858.CD010069.pub2] - DOI - PubMed

Publication types

MeSH terms